Search results
Results from the WOW.Com Content Network
Kweku Hanson#Class action lawsuit against Ocwen Federal FSB; Lead contamination in Washington, D.C. drinking water#Class-action lawsuit; Long-term effects of benzodiazepines#Class-action lawsuit; Lowe's#Lawsuits; MMR vaccine controversy#MMR litigation starts; Mannatech#Securities Exchange Act class-action lawsuit; Match.com#Controversy
The state lawsuits sought recovery for Medicaid and other public health expenses incurred in the treatment of smoking-induced illnesses. Importantly, the defenses of personal responsibility that were so effective for the tobacco industry in suits by private individuals were inapplicable to the causes of action alleged by the states.
False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma [15] $601 million Off-label promotion Oxycontin: False Claims Act 2010 Allergan [16] $600 million Off-label promotion Botox: False Claims Act, FDCA 2010 AstraZeneca [17] $520 million Off-label promotion, kickbacks Seroquel: False Claims Act 2007 Bristol-Myers Squibb [18] $515 million
Davis is a plaintiff in a Tennessee class-action lawsuit contesting the state’s Medicaid eligibility process. She and her children lost their coverage in 2019 after Tennessee launched a Deloitte ...
Parents of two children with disabilities are suing an Indiana agency in federal court over changes to attendant care services they say violate the Americans with Disabilities Act and federal ...
Facebook recently paid 1.4 million Illinois residents $397 in 2022 as part of a class action lawsuit for facial recognition breaches through its “Tag Suggestions” feature, per CNBC. Google is ...
In lawsuits and complaints with state law enforcement officials, hospice families claim their directives were ignored and that loved ones received too many medications, or not enough. The most-watched federal lawsuit, filed last May, accuses Vitas in unusually strong language of harming patients in the pursuit of profits.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...